PPL-003

PPL-003 is a code name for an investigational anti-inflammatory peptide drug candidate developed using the CellPorter platform. It is designed as a fusion protein that targets and inhibits Nuclear factor NF-kappa-B complex (NF-κB), a key transcription factor involved in inflammatory processes. The drug is being developed primarily for topical ophthalmic use, with its lead indications being dry eye disease and uveitis. Preclinical studies in animal models have demonstrated steroid-like efficacy without the adverse effects commonly associated with steroids, such as glaucoma or cataract formation. The developer aims to advance PPL-003 into clinical trials to address unmet needs in inflammatory ocular diseases.